Equities analysts predict that Myokardia Inc (NASDAQ:MYOK) will post sales of $5.63 million for the current quarter, according to Zacks. Two analysts have issued estimates for Myokardia’s earnings. Myokardia posted sales of $28.55 million during the same quarter last year, which would indicate a negative year over year growth rate of 80.3%. The business is scheduled to report its next quarterly earnings results on Monday, March 12th.
On average, analysts expect that Myokardia will report full year sales of $5.63 million for the current financial year, with estimates ranging from $22.50 million to $25.00 million. For the next fiscal year, analysts expect that the business will report sales of $31.50 million per share, with estimates ranging from $22.50 million to $40.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Myokardia.
Myokardia (NASDAQ:MYOK) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.42). Myokardia had a negative net margin of 53.49% and a negative return on equity of 14.92%. The company had revenue of $5.63 million during the quarter, compared to analysts’ expectations of $6.10 million. During the same quarter in the previous year, the company posted ($0.35) earnings per share. Myokardia’s quarterly revenue was up 58.6% compared to the same quarter last year.
In related news, Director Kevin P. Starr sold 816,326 shares of the firm’s stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $42.00, for a total value of $34,285,692.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Anastasios Gianakakos sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $41.09, for a total transaction of $123,270.00. Following the completion of the sale, the insider now directly owns 512,117 shares of the company’s stock, valued at approximately $21,042,887.53. The disclosure for this sale can be found here. In the last three months, insiders sold 831,626 shares of company stock valued at $34,921,501. 33.40% of the stock is currently owned by company insiders.
Several institutional investors have recently modified their holdings of MYOK. Quantbot Technologies LP acquired a new stake in Myokardia during the 3rd quarter worth $202,000. Dimensional Fund Advisors LP acquired a new stake in Myokardia during the 3rd quarter worth $212,000. Cubist Systematic Strategies LLC acquired a new stake in Myokardia during the 3rd quarter worth $355,000. TD Asset Management Inc. acquired a new stake in Myokardia during the 3rd quarter worth $364,000. Finally, Nationwide Fund Advisors grew its holdings in Myokardia by 36.3% during the 2nd quarter. Nationwide Fund Advisors now owns 9,729 shares of the biotechnology company’s stock worth $127,000 after acquiring an additional 2,591 shares during the period. 63.61% of the stock is owned by institutional investors and hedge funds.
Myokardia (NASDAQ MYOK) opened at $42.30 on Friday. Myokardia has a one year low of $10.55 and a one year high of $49.55. The stock has a market cap of $1,520.00 and a P/E ratio of -57.16.
TRADEMARK VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/06/zacks-analysts-expect-myokardia-inc-myok-will-post-quarterly-sales-of-5-63-million.html.
Myokardia Company Profile
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.